MID-VOLUME · FEMALE-LED
methocarbamol Side Effects
methocarbamol (also sold as Robaxin) sits MID-VOLUME #228 of 524 by FAERS report count. Lead signal: FEMALE-LED - 70% of sex-coded reports are female (13,996 F / 5,871 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 21,191
- FAERS reports
FDA Adverse Event Reporting System extract for methocarbamol. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-MID. How figures are compiled.
methocarbamol reporting skew - 70% of sex-coded reports are female (13,996 F / 5,871 M). Volume band MID-VOLUME #228 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for methocarbamol (Robaxin) (21,191 reports). Signature FEMALE-LED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
PAIN leads 1,639 of 21,191 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (70% of sex-coded rows)
Age peak 45-64 (6,430 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (1,643 reports, 7.8%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 528 |
| COMPLETED SUICIDE | 323 |
| TOXICITY TO VARIOUS AGENTS | 169 |
| CARDIAC ARREST | 132 |
| CARDIO-RESPIRATORY ARREST | 109 |
| PNEUMONIA | 83 |
| DYSPNOEA | 80 |
| RESPIRATORY ARREST | 73 |
| RENAL FAILURE | 72 |
| FALL | 69 |
| ACUTE KIDNEY INJURY | 61 |
| HYPERTENSION | 61 |
| OVERDOSE | 60 |
| ANXIETY | 56 |
| FATIGUE | 56 |
| SEPSIS | 56 |
| BACK PAIN | 54 |
| CHRONIC KIDNEY DISEASE | 54 |
| PAIN | 52 |
| CONFUSIONAL STATE | 48 |
Reactions in Hospitalization Reports
Hospitalization mid-share (6,345, 29.9%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| FALL | 588 |
| PAIN | 534 |
| NAUSEA | 509 |
| PNEUMONIA | 470 |
| DYSPNOEA | 466 |
| FATIGUE | 434 |
| DIARRHOEA | 378 |
| HEADACHE | 365 |
| VOMITING | 365 |
| BACK PAIN | 361 |
| HYPERTENSION | 347 |
| ANXIETY | 332 |
| ASTHENIA | 320 |
| ARTHRALGIA | 301 |
| PAIN IN EXTREMITY | 300 |
| DEPRESSION | 297 |
| DIZZINESS | 295 |
| PYREXIA | 276 |
How to read methocarbamol FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-MID)
FAERS holds 21,191 voluntary reports linked to methocarbamol (Robaxin), 2004-2025. Death is listed on 1,643 (7.8%). Hospitalization appears on 6,345 (29.9%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-MID as signal-detection rates next to 70% of sex-coded reports are female (13,996 F / 5,871 M).
Read with methocarbamol
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 21,352 FAERS cases (Δ 161 heavier vs methocarbamol); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 21,004 FAERS cases (Δ 187 lighter vs methocarbamol); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 20,856 FAERS cases (Δ 335 lighter vs methocarbamol); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 20,677 FAERS cases (Δ 514 lighter vs methocarbamol); DEATH-HEAVY · HOSP-HEAVY · MALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 54.4 pp vs methocarbamol's DEATH-HEAVY): CASELOAD · HOSP-MID.
methocarbamol stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.